The absence of intrahepatic cholestasis in patients with complete MYO5B deficiency, suggest that a gene therapy that blocks the expression of MYO5B with motor domain missense mutations may partly correct the mislocalization of apical proteins and in theory could be a feasible approach to treat PFIC6. This evidence concerns the gene MYO5B and intrahepatic cholestasis.